Dr. Lal PathLabs Limited (DLPL), one of India’s leading diagnostic chains, has significantly enhanced its genomics capabilities by integrating Illumina’s NovaSeq X Series into its dedicated genomics arm, Genevolve.
State-of-the-art sequencing technology
The NovaSeq X system uses Illumina’s breakthrough XLEAP‑SBS chemistry. With high throughput, outstanding accuracy, and energy-efficient design, it can sequence over 20,000 whole human genomes per year—more than twice the capacity of previous Illumina models.
Boosting speed and precision
This integration enables DLPL to deliver faster turnaround times and greater sequencing depth—critical for precise, AI-powered healthcare insights.
Enabling large-scale genomic research in India
From population genomics to rare disease detection and personalized medicine, this deployment accelerates India’s journey toward wide-scale genomics-based healthcare solutions.
SOURCE- ECONOMICS TIME
State-of-the-art sequencing technology
The NovaSeq X system uses Illumina’s breakthrough XLEAP‑SBS chemistry. With high throughput, outstanding accuracy, and energy-efficient design, it can sequence over 20,000 whole human genomes per year—more than twice the capacity of previous Illumina models.
Boosting speed and precision
This integration enables DLPL to deliver faster turnaround times and greater sequencing depth—critical for precise, AI-powered healthcare insights.
Enabling large-scale genomic research in India
From population genomics to rare disease detection and personalized medicine, this deployment accelerates India’s journey toward wide-scale genomics-based healthcare solutions.
SOURCE- ECONOMICS TIME
Dr. Lal PathLabs Limited (DLPL), one of India’s leading diagnostic chains, has significantly enhanced its genomics capabilities by integrating Illumina’s NovaSeq X Series into its dedicated genomics arm, Genevolve.
State-of-the-art sequencing technology
The NovaSeq X system uses Illumina’s breakthrough XLEAP‑SBS chemistry. With high throughput, outstanding accuracy, and energy-efficient design, it can sequence over 20,000 whole human genomes per year—more than twice the capacity of previous Illumina models.
Boosting speed and precision
This integration enables DLPL to deliver faster turnaround times and greater sequencing depth—critical for precise, AI-powered healthcare insights.
Enabling large-scale genomic research in India
From population genomics to rare disease detection and personalized medicine, this deployment accelerates India’s journey toward wide-scale genomics-based healthcare solutions.
SOURCE- ECONOMICS TIME
